¡ã Çѱ¹¾àÁ¦ÇÐȸ°¡ 21ÀϺÎÅÍ 22ÀϱîÁö ¼¿ï ´õÄÉÀÌÈ£ÅÚ¿¡¼ 2019³â Çѱ¹¾àÁ¦ÇÐȸ ÃÑȸ ¹× ±¹Á¦Çмú´ëȸ¸¦ °³ÃÖÇÑ´Ù.
21~22ÀÏ, ¼¿ï ´õ ÄÉÀÌÈ£ÅÚ¼...Çѱ¹¾àÁ¦ÇÐȸ À̹üÁø ±³¼ö(¾ÆÁÖ´ë ¾à´ëÇÐÀå) ÃßÁø
±ÇÀÍÂù ±³¼ö, ¡®Drug delivery and molecular imaging µî 8°³ÁÖÁ¦...´ë±Ô¸ð ±¹Á¦ÇÐȸ
Çѱ¹¾àÁ¦ÇÐȸ(ȸÀå À̹üÁø.»çÁø/¾ÆÁÖ´ë ¾à´ëÇÐÀå)°¡ 2019³â Çѱ¹¾àÁ¦ÇÐȸ ÃÑȸ ¹× ±¹Á¦Çмú´ëȸ¸¦ °³ÃÖÇÑ´Ù.
2019³â Çѱ¹¾àÁ¦ÇÐȸ ÃÑȸ ¹× ±¹Á¦Çмú´ëȸ´Â 11¿ù 21ÀÏ ¿ÀÀü 10½Ã¿¡ °³¸·µÅ 22ÀϱîÁö ÀÌƲ°£ ¼¿ï ´õÄÉÀÌÈ£ÅÚ¿¡¼ ¡®Dynamic Revolutions in Pharmaceutical Sciences and Technology¡¯¶ó´Â ÁÖÁ¦·Î °³ÃֵȴÙ.
À̹ø Çмú´ëȸ¿¡¼´Â ¹Ì±¹ KIST-Dana Farber Cancer Institute ±ÇÀÍÂù ±³¼öÀÇ ¡®Drug delivery and molecular imaging¡¯, °è¸í´ëÇб³ ¼Õµ¿È¯ ±³¼öÀÇ ¡®Antifibrotic therapy by the modulation of apoptosis¡¯¶ó´Â ÁÖÁ¦ÀÇ ±âÁ¶°¿¬À» ºñ·ÔÇÏ¿© 8°³ÀÇ ÁÖÁ¦ ºÐ¾ß (Biotechnology & Drug Delivery / Biopharmaceutics, Pharmacokinetics & Metabolism / Polymer Science & Materials / Regulatory Science & Policy / Physical Pharmacy & Formulation Design / Drug Design & Development / Pharmaceutical Quality & Analysis / Manufacturing Science & Engineering)¿¡ °ÉÃÄ ±¹³» »Ó ¾Æ´Ï¶ó ¹Ì±¹, Áß±¹, ÀϺ», Àεµ, ³×´ú¶õµå, µ§¸¶Å©, Çë°¡¸®, ½Ì°¡Æ÷¸£¿¡¼ ÃÊûµÈ ¿¬ÀÚµé ÃÑ 34¸íÀÌ ¾àÁ¦ÇÐ ºÐ¾ßÀÇ Ãֽſ¬±¸¿¡ ´ëÇØ °¿¬ÀÌ ÁøÇàµÈ´Ù.
Biotechnology & Drug Delivery 1 ¼¼¼ÇÀº GC³ì½ÊÀÚ, Regulatory Science & Policy ¼¼¼ÇÀº ½Ä¾àóÀÇ ÈÄ¿øÀ¸·Î ÀÌ·ç¾îÁø´Ù.
Çмú °¿¬ ¿Ü¿¡µµ Â÷¼¼´ë ¿¬±¸ÀÚ À°¼º ¹× Áö¿øÀ» À§ÇØ ¡®Preformulation considerations for biopharmaceutics classification system (BCS)¡¯ À̶ó´Â ÁÖÁ¦·Î Cutting-edge techniques in solubility evaluation, Recent solidification technologies for liquid-based formulations, Challenges to improve the biopharmaceutical properties of BCS Class III/IV candidates and drug development strategy, How to prepare for a job interview & How to build a successful career¶ó´Â ±³À° ÇÁ·Î±×·¥ÀÌ Ã¹ ³¯ ¿ÀÀü¿¡ ÁøÇàµÈ´Ù.
¶ÇÇÑ, µÑ° ³¯ ¿ÀÈÄ¿¡ ¡®Young Scientist Session¡¯À» º°µµ·Î °³ÃÖÇÔÀ¸·Î½á ´ëÇпø»ý µî ÀþÀº ¿¬±¸ÀÚµéÀÇ Àû±ØÀûÀÎ Çмú´ëȸ Âü¿©¸¦ À¯µµ ÇÒ ¿¹Á¤ÀÌ´Ù.
Çѱ¹¾àÁ¦ÇÐȸ À̹üÁø ȸÀå(¾ÆÁÖ´ëÇб³ ¾àÇдëÇÐ)Àº ¡°Çѱ¹¾àÁ¦ÇÐȸ´Â À̹ø ±¹Á¦Çмú´ëȸ¸¦ ÅëÇØ ¾à¹° Àü´Þ ¹× °³¹ß, Á¦¾à, ±ÔÁ¦ °úÇÐ ¹× ȯÀÚ Áß½ÉÀÇ ¾à¹° Àü´Þ ¹× µðÁöÅÐ ÀÇÇÐÀ» Æ÷ÇÔÇÑ Ã·´Ü ±â¼úÁ¤º¸¸¦ Á¦°øÇÏ°í Çаè, Á¦¾à »ê¾÷ ¹× Á¤ºÎÀÇ ¿¬±¸ÀÚ¿Í Àü¹®°¡°¡ 4Â÷ »ê¾÷ Çõ¸í ½Ã´ëÀÇ ÃֽŠ¿¬±¸°á°ú, »ê¾÷ µ¿Çâ ¹× ±ÔÁ¦ ¾÷µ¥ÀÌÆ®¸¦ °øÀ¯ÇÏ°í ³×Æ®¿öÅ· ¹× ÇмúÀû ±³·ù ±âȸ¸¦ ¸¶·ÃÇÏ°íÀÚ ÇÏ¿´À¸¹Ç·Î, ±¹³» Á¦¾à »ê¾÷°è ¹× °ü·Ã Çа迡¼ ¸¹ÀÌ Âü¼®ÇØ Çѱ¹¾àÁ¦ÇÐȸ ±¹Á¦Çмú´ëȸ¸¦ Áñ±â½Ã±â¸¦ Èñ¸ÁÇÑ´Ù.¡±¶ó°í ¸»Çß´Ù.
ÀÌ ÇÁ·Î±×·¥Àº ÇÐȸ Âü°¡µî·ÏÀÚ Áß ½ÅûÀڵ鿡°Ô º°µµÀÇ ¼ö°·á ¾øÀÌ ¹«·á·Î Á¦°øµÈ´Ù.
±¹Á¦Çмú´ëȸ¿Í °ü·ÃµÈ ÀÚ¼¼ÇÑ »çÇ×Àº Çѱ¹¾àÁ¦ÇÐȸ ȨÆäÀÌÁö (www.kspst.or.kr)¿¡¼ È®ÀÎÇÒ ¼ö ÀÖ´Ù.